CN113073114A - 一种抗非洲猪瘟克隆猪的制备方法 - Google Patents
一种抗非洲猪瘟克隆猪的制备方法 Download PDFInfo
- Publication number
- CN113073114A CN113073114A CN202110370768.8A CN202110370768A CN113073114A CN 113073114 A CN113073114 A CN 113073114A CN 202110370768 A CN202110370768 A CN 202110370768A CN 113073114 A CN113073114 A CN 113073114A
- Authority
- CN
- China
- Prior art keywords
- pig
- gene
- cas9
- intron
- sgrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000282898 Sus scrofa Species 0.000 title claims abstract description 85
- 208000007407 African swine fever Diseases 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 76
- 210000004027 cell Anatomy 0.000 claims abstract description 49
- 108091033409 CRISPR Proteins 0.000 claims abstract description 34
- 241000701386 African swine fever virus Species 0.000 claims abstract description 32
- 230000008685 targeting Effects 0.000 claims abstract description 25
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 20
- 101710118425 Inner membrane protein pE248R Proteins 0.000 claims abstract description 19
- 241000700605 Viruses Species 0.000 claims abstract description 19
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract description 16
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 9
- 210000004291 uterus Anatomy 0.000 claims abstract description 5
- 108020004414 DNA Proteins 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 16
- 230000004927 fusion Effects 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 238000012546 transfer Methods 0.000 claims description 13
- 108091034117 Oligonucleotide Proteins 0.000 claims description 11
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 8
- 238000001976 enzyme digestion Methods 0.000 claims description 7
- 108091008146 restriction endonucleases Proteins 0.000 claims description 6
- 238000000137 annealing Methods 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 210000000287 oocyte Anatomy 0.000 claims description 4
- 230000035935 pregnancy Effects 0.000 claims description 3
- 238000004520 electroporation Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000010363 gene targeting Methods 0.000 claims 1
- 210000003370 receptor cell Anatomy 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 5
- 238000009395 breeding Methods 0.000 abstract description 3
- 230000001488 breeding effect Effects 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 238000003198 gene knock in Methods 0.000 abstract description 2
- 238000012239 gene modification Methods 0.000 abstract description 2
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 230000005017 genetic modification Effects 0.000 abstract description 2
- 235000013617 genetically modified food Nutrition 0.000 abstract description 2
- 230000000644 propagated effect Effects 0.000 abstract description 2
- 238000010374 somatic cell nuclear transfer Methods 0.000 abstract 1
- 241000282887 Suidae Species 0.000 description 17
- 230000003321 amplification Effects 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 239000012528 membrane Substances 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010370 cell cloning Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 210000001163 endosome Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000003101 oviduct Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006395 clathrin-mediated endocytosis Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009351 contact transmission Effects 0.000 description 1
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Environmental Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种抗非洲猪瘟克隆猪的制备方法,属于动物基因工程和基因遗传修饰领域。用CRISPR/Cas9基因敲入技术,将CRISPR/Cas9打靶载体,与猪Rosa26基因donor载体共转入猪成纤维细胞中,获得阳性细胞克隆,阳性克隆中猪Rosa26基因的第1内含子被敲入能表达特异性靶向敲除病毒pE248R基因的sgRNA‑Cas9的基因,使病毒在体内繁殖时被靶向敲除pE248R基因,使猪具有ASFV抗性;再通过体细胞核移植技术获得克隆胚胎;将克隆胚胎移入猪子宫内妊娠获得克隆猪。本发明首次将sgRNA‑Cas9系统敲入猪体内,并使其稳定表达而获得ASFV抗性,为抗非洲猪瘟育种研究奠定基础。
Description
技术领域
本发明涉及动物基因工程和基因遗传修饰领域,具体涉及一种抗非洲猪瘟克隆猪的制备方法。
背景技术
非洲猪瘟(African swine fever,ASF)是由非洲猪瘟病毒(African swine fevervirus,ASFV)引起的一种急性、热性、高度接触性传染病,通常表现出全身出血、神经症状和呼吸困难等临床症状,具有病程时间短、高病死率等特征。ASFV是一种单分子线状双链DNA病毒,属于双链DNA病毒目,非洲猪瘟病毒科,非洲猪瘟病毒属,是ASFV家族中的唯一成员,也是唯一的虫媒DNA病毒。ASF的主要传染源是感染猪和带毒猪,受感染的组织、血液、猪的分泌物和排泄物中都含有病毒,病毒可附着在饲料、运输车等物体进行传播,除直接接触传播外,ASFV还能通过蜱虫进行传播。2018年8月,我国确诊了首例ASF疫情,随后ASFV在我国快速传播,目前全国已有31个省、自治区、直辖市和香港特别行政区暴发了ASF疫情,因缺乏有效的ASFV疫苗和治疗方法,ASF对我国养猪业造成了巨大损失。
目前认为ASFV的入侵途径主要有网格蛋白介导的内吞途径(CME)和巨胞饮途径。有报道指出CD163是ASFV入侵的受体。但Popescu等的研究表明该受体在某些情况下对于ASFV感染不是必需的。因此参与病毒进入细胞的受体身份目前仍未知的,对抗病育种的开展造成极大的困扰。
病毒蛋白pE248R位于病毒内膜,其参与ASFV进入早期进程。ASFV通过CME或巨胞饮途径进入到细胞,需要从内吞途径形成的内体中脱模并被释放到胞质中。ASFV脱膜涉及多囊泡晚期内体中病毒体外层(外膜和蛋白衣壳)的损失,以及内膜与内体的后期融合,从而将裸核释放到细胞质中。其中pE248R与病毒的脱模密切相关。Rodríguez等使用pE248R缺陷病毒颗粒进行研究,其发现pE248R缺陷病毒的感染力至少降低了100倍,而pE248R蛋白的缺失既不影响病毒的结合,也不影响病毒的内化,但没有引起细胞病变,并能使早期和晚期的基因表达受到损害,这表明该蛋白对于病毒的感染和早期进入是必需的。而近期的研究也指出该蛋白参与内膜与多囊泡内体膜的融合,是核释放关键因素。
Rosa26基因座是基因组中的安全位点,在多种物种中都得到保存,包括小鼠,人类,大鼠,猪,绵羊和兔子。猪Rosa26(pRosa26)基因座的序列已被完全鉴定,并且pRosa26启动子已被鉴定。该猪内源性启动子通过避免DNA甲基化而适于以高且稳定的方式驱动外源基因表达。因此pRosa26是合适的插入外源基因的位点。
发明内容
针对现有技术中存在的问题,本发明的目的是提供一种抗非洲猪瘟猪的制备方法,是利用CRISPR-Cas9系统介导的同源重组将表达针对病毒蛋白pE248R基因的sgRNA-Cas9基因片段敲入到猪Rosa26基因座中,以获得抗非洲猪瘟猪。
为实现上述目的,本发明提供了如下方案:
本发明提供一种猪Rosa26基因donor载体,将猪Rosa26基因的第1内含子敲入表达靶向非洲猪瘟病毒pE248R基因的sgRNA-Cas9序列;猪Rosa26基因第1内含子的核苷酸序列如SEQ ID NO.1所示;所述表达靶向非洲猪瘟病毒pE248R基因的sgRNA-Cas9基因序列如SEQID NO.2所示。
本发明提供一种所述猪Rosa26基因donor载体的制备方法,具体制备方法包括:
S1.利用猪细胞基因组DNA为模板扩增出3780bp的猪Rosa26基因第1内含子同源左臂;将表达特异性靶向病毒pE248R基因的sgRNA-Cas9基因与猪Rosa26基因第1内含子同源左臂融合,得到融合片段1;
S2.利用猪细胞基因组DNA为模板扩增出1935bp的猪Rosa26基因第1内含子同源右臂;将融合片段1与猪Rosa26基因第1内含子同源右臂融合,得到融合片段2;
S3.用SacII和SphI限制性内切酶分别对融合片段2和载体LoxPneoLoxP2PGK进行双酶切,然后连接得到猪Rosa26基因donor载体。
进一步地,步骤S1所述猪Rosa26基因第1内含子同源左臂核苷酸序列如SEQ IDNO.5所示;步骤S2所述猪Rosa26基因第1内含子同源右臂核苷酸序列如SEQ ID NO.8所示。
进一步地,用于扩增猪Rosa26基因第1内含子同源左臂的引物对的核苷酸序列如SEQ ID NO.6~7所示;用于扩增猪Rosa26基因第1内含子同源右臂的引物对的核苷酸序列如SEQ ID NO.9~10所示。
进一步地,用于扩增靶向敲除病毒pE248R基因的sgRNA-Cas9基因的引物对的核苷酸序列如SEQ ID NO.3~4所示。
本发明提供一种CRISPR/Cas9打靶载体,其含有特异性靶向猪Rosa26基因第1内含子的sgRNA,所述sgRNA的核苷酸序列如SEQ ID NO.12所示。
进一步地,具体制备方法为:先根据sgRNA序列合成互补配对的如SEQ ID NO.13~14所示的寡聚核苷酸px459-F和px459-R,再将寡聚核苷酸在94℃,5min,再35℃,10min后立即放冰上进行退火处理,最后将其与经限制性内切酶BbsI进行酶切过夜并回收的px459骨架载体连接。
本发明还提供一种抗非洲猪瘟克隆猪的制备方法,将所述CRISPR/Cas9打靶载体与所述猪Rosa26基因donor载体共同转入猪成纤维细胞中,获得阳性细胞克隆;以阳性细胞克隆为核移植供体细胞,卵母细胞为核移植受体细胞;将克隆胚胎移入猪子宫内妊娠,获得基因敲入后的抗非洲猪瘟克隆猪。
进一步地,所述CRISPR/Cas9打靶载体与猪Rosa26基因donor载体共同转入猪成纤维细胞的具体步骤为:CRISPR/Cas9打靶载体与猪Rosa26基因donor载体按物质的量1:1~4的比例混合,用电穿孔的方法将其转入1x106个猪成纤维细胞。
本发明公开了以下技术效果:
本发明首次在猪上利用CRISPR/Cas9技术介导同源重组,将对靶向敲除ASFVpE248R的sgRNA-Cas9系统敲入猪Rosa26基因中,使其稳定表达针对病毒蛋白的sgRNA-Cas9从而获得ASFV抗性,为猪利用CRISPR/Cas9技术介导同源重组进行基因编辑研究及抗非洲猪瘟育种研究奠定基础。
附图说明
图1是本发明中将猪Rosa26基因第1内含子替换成特异性靶向敲除病毒pE248R基因的sgRNA-Cas9基因的示意图;
图2是本发明实施例1中猪Rosa26基因donor载体的构建流程图;
图3是本发明实施例2中T7E1酶切法鉴定在猪成纤维细胞上px459质粒对基因组的切割情况;其中试验组为px459质粒转染后的猪成纤维细胞基因组,WT组为野生型猪成纤维细胞基因组;
图4是本发明实施例4中新生仔猪的Western blot检测结果图。
具体实施方式
下面结合附图进一步说明本发明的实施例,该详细说明不应认为是对本发明的限制,而应理解为是对本发明的某些方面、特性和实施方案的更详细的描述。
应理解本发明中所述的术语仅仅是为描述特别的实施方式,并非用于限制本发明。另外,对于本发明中的数值范围,应理解为还具体公开了该范围的上限和下限之间的每个中间值。在任何陈述值或陈述范围内的中间值以及任何其他陈述值或在所述范围内的中间值之间的每个较小的范围也包括在本发明内。这些较小范围的上限和下限可独立地包括或排除在范围内。
除非另有说明,否则本文使用的所有技术和科学术语具有本发明所述领域的常规技术人员通常理解的相同含义。虽然本发明仅描述了优选的方法和材料,但是在本发明的实施或测试中也可以使用与本文所述相似或等同的任何方法和材料。本说明书中提到的所有文献通过引用并入,用以公开和描述与所述文献相关的方法和/或材料。在与任何并入的文献冲突时,以本说明书的内容为准。
在不背离本发明的范围或精神的情况下,可对本发明说明书的具体实施方式做多种改进和变化,这对本领域技术人员而言是显而易见的。由本发明的说明书得到的其他实施方式对技术人员而言是显而易见得的。本申请说明书和实施例仅是示例性的。
关于本文中所使用的“包含”、“包括”、“具有”、“含有”等等,均为开放性的用语,即意指包含但不限于。
本发明采用CRISPR/Cas9基因敲入技术,构建CRISPR/Cas9打靶载体,并将其与猪Rosa26基因donor载体共转入猪成纤维细胞中,获得阳性细胞克隆,所述阳性细胞克隆中猪Rosa26基因的第1内含子(如SEQ ID NO.1所示)被敲入能表达特异性靶向敲除ASFV病毒pE248R基因的sgRNA-Cas9的基因(如SEQ ID NO.2所示)中,其结构见图1,使病毒在体内繁殖时被靶向敲除pE248R基因,使猪具有ASFV抗性。
实施例1猪Rosa26基因donor载体的构建
S1.将能表达针对ASFV pE248R的sgRNA-Cas9基因序列和同源左臂融合;由上海生工合成sgRNA-Cas9基因序列并测序验证,再以其为模板进行扩增,扩增所采用的引物(如SEQ ID NO.3~4所示)为F5’-GAGGGCCTATTTCCCATGAT-3’和R5’-TTATCGTCCGT ACGACCCCT-3’,纯化PCR产物并测序验证正确。以猪细胞基因组DNA为模板,扩增出3780bp的猪Rosa26基因第1内含子同源左臂(如SEQ ID NO.5所示)。扩增体系为:猪细胞基因组DNA,20μL;GreenTaq Mix,25μL;pRosa26-Lelf-F’(100μM)2μL;pRosa26-Lelf-R’(100μM)2μL;ddH2O,1μL。扩增程序为:95℃,3min;95℃,15sec,60℃,15sec,72℃,4min,35次循环;72℃,5min。扩增所用引物对(如SEQ ID NO.6~7所示)为pRosa26-Lelf-F’:ATGCCGCGGGAAGCGGCCCTAGAA和pRosa26-Lelf-R':TTTCGTGTTTTCTC ATTCACCTGT,下划线为SacII酶切位点,测序验证正确。将sgRNA-Cas9基因与同源左臂进行融合,命名为融合片段1,测序验证正确。
S2.以猪细胞基因组DNA为模板,扩增出1935bp的猪Rosa26基因第1内含子同源右臂(如SEQ ID NO.8所示)。扩增体系为:猪细胞基因组DNA,20μL;Green Taq Mix,25μL;pRosa26-Lelf-F’(100μM)2μL;pRosa26-Lelf-R’(100μM)2μL;ddH2O,1μL。扩增程序为:95℃,3min;95℃,15sec,60℃,15sec,72℃,2min,35次循环;72℃,5min。扩增所用引物对(如SEQ ID NO.9~10所示)为pRosa26-Right-F':TGTTTATAAATGGCAACTAAAACCC和pRosa26-Right-R':CCCAGGAACTTTT GCATGCTGCA,下划线为SphI酶切位点,测序验证正确。将融合片段1与同源右臂融合,命名为融合片段2(如SEQ ID NO.11所示),测序验证正确。
S3.将载体LoxPneoLoxP2PGK用SacII和SphI限制性内切酶于37℃进行消化,回收较大的片段,回收得到的片段与酶切(SacII和SphI)后的融合片段2用T4 DNA连接酶于16℃进行连接,得到最终的猪Rosa26基因donor载体,见图2。
实施例2CRISPR-Cas9打靶载体的构建
S1.利用在线设计网站(https://benchling.com/)对猪Rosa26基因的第1内含子的打靶位点进行预测;根据自我评估和预测结果中的评分,从候选的靶位点钟选择评分最高的一个,其sgRNA序列(如SEQ ID NO.12所示)为ACTGCTTCTAGACCAACCAA。根据sgRNA序列合成互补配对的寡聚核苷酸,如表1所示,其中小写字母为酶切位点。
表1寡聚核苷酸序列
名称 | 序列(5'-3') |
px459-F(如SEQ ID NO.13所示) | caccGACTGCTTCTAGACCAACCAA |
px459-R(如SEQ ID NO.14所示) | aaacTTGGTTGGTCTAGAAGCAGTC |
S2.构建打靶载体
使用表1的寡聚核苷酸,构建过程为:94℃,5min,再35℃,10min,然后立即放冰上,对寡聚核苷酸进行退火,px459骨架载体用限制性内切酶BbsI进行酶切过夜,回收后,与退火的寡聚核苷酸16℃连接3h。通过常规转化法进行转化、涂板。待单菌落长成后,挑取数个扩大培养并测序。测序验证正确,说明本发明成功构建CRISPR-Cas9打靶载体。
S3.阳性单菌落扩大培养
具体步骤为:a.初始培养,用接种环挑取阳性单菌落,加入盛有10mL LB培养基的灭菌管中,37℃,250rpm,培养5h-28h;b.扩大培养,将过夜培养液按体积1:500的比例转移到盛有100mL LB培养基的三角瓶中,37℃,250rpm,培养10h至24h。
S4.px459质粒去内毒素提取
按照质粒区内毒素大提试剂盒上提供的方法,提取px459质粒,所提的质粒用于细胞的转染。
S5.细胞转染
细胞转染采用Lonza Nucleofector进行电转。具体流程如下:a.将消化并收集的6孔细胞培养板中一个孔的猪成纤维细胞(约1×106个)、4μg px459质粒和100μLNucleofector试剂混匀,装入电击杯用T-016程序进行电击转染;b.电击结束后,沿电击杯内壁加入37℃预热的成纤维细胞培养基500μL,将细胞接种于6孔细胞培养板的一个孔内;c.用无筛选药物的成纤维细胞培养基于37℃,5%CO2培养箱培养。
S6.打靶效率的检测
按照基因组提取试剂盒上提供的方法,提取细胞基因组;以提取的基因组和野生型猪成纤维细胞基因组(WT组)为模板,用KOD DNA聚合酶进行PCR,扩增出528bp的片段,所使用的引物F(如SEQ ID NO.15所示):5’-TGTGGACATTTCTAGTGTCAGGA-3’和R(如SEQ IDNO.16所示):5’-AGTGACTCA CCACATCTTCTTT-3’。扩增条件为94℃,2min;90℃,30sec;60℃,30sec;65℃,60sec;70℃,6min;45个循环,1.0%琼脂糖电泳观察结果,然后回收PCR产物,测浓度。取400ng回收产物进行退火,从95℃程序降温至4℃。退火后的产物用T7E1酶进行酶切,体系为:退火产物10μL,NEB buffer2 2μL,T7E1 0.5μL,ddH20补足至20μL。酶切完成后用2%琼脂糖电泳观察结果,结果显示(见图3),该质粒能在猪成纤维细胞上发挥切割基因组的作用。
实施例3阳性细胞单克隆的筛选及鉴定
S1.阳性单克隆细胞的筛选
消化并收集孔细胞培养板中一个孔的猪成纤维细胞(约1×106个),将实施例2构建的打靶载体px459和实施例1构建得到的猪Rosa26基因donor载体,按物质的量1:2的比例混合,取总质量6μg,按实施例2中的S5的方法进行转染后,放至CO2培养箱中,37℃培养。48h后细胞汇合度达到80%-90%,此时将1个孔的细胞平均分到8个10cm培养皿中。24后细胞贴壁,将培养基更换为含G418(500μg/mL)的成纤维细胞培养基,每3~4d换一次液,培养基仍然为含G418(500μg/mL)的成纤维细胞培养基。细胞培养7~10d后,可以观察到细胞克隆点形成。在显微镜下找到抗性细胞克隆点,用Marker笔做标记,倒掉培养基,PBS溶液清洗一次,用细胞克隆环将抗性细胞克隆点罩住,加入10~30μL在37℃预热的胰蛋白酶消化液,37℃消化细胞3min左右,加入细胞培养基终止消化反应,将消化下来的细胞接种到48孔细胞培养板中培养。待细胞汇合度达到90%时,消化细胞,接种到12孔细胞培养板中继续培养,原48孔细胞培养板中的未被消化下来的细胞也继续培养以供提取细胞基因组,细胞继续扩大培养至6孔细胞培养板,按照猪胚胎成纤维细胞冻存方法进行抗性细胞冻存。
S2.阳性细胞单克隆的鉴定
挑取70个细胞单克隆进行鉴定:将所挑取的细胞单克隆送由上海生工公司进行PCR及测序验证,验证sgRNA-Cas9是否成功敲入到指定位点。验证结果显示,70个细胞单克隆中有3个为阳性单克隆。
实施例4抗ASFV克隆猪的制备与鉴定
S1.抗ASFV克隆猪的制备
以实施例3获得的成功发生同源重组的阳性细胞为核移植供体细胞,以体外成熟的初情期前母猪卵母细胞为核移植受体细胞,将核移植供体细胞移入去核的卵母细胞,经电融合与激活,构建成克隆胚胎,挑选形态优良的克隆胚胎用手术法移入自然发情的经产母猪(6头)子宫内进行妊娠,手术法胚胎移植步骤为舒泰常规麻醉,在手术架上仰卧绑定,腹中线做一个长约的手术切口,曝露卵巢、输卵管及子宫,用胚胎移植管沿输卵管伞部进入约5cm,将胚胎(400枚以上/头)移植到输卵管壶腹部一峡部结合处。胚胎移植后30天B型超声波检测妊娠与否。
S2.新生仔猪的基因鉴定
从新生猪的耳部采取组织1g~5g立即用液氮速冻,保存于-80℃,用足量干冰寄送上海生工公司进行测序鉴定。结果显示有8头仔猪中有6头阳性仔猪。
S3.新生仔猪的Western blot检测
取克隆仔猪耳和尾组织各1~5g,普通商品猪耳和尾组织各1~5g作为阴性对照。把组织剪切成细小的碎片,加入1.5mL裂解液(裂解液在使用前数分钟加入PMSF,使的PMSF最终浓度为10μM)。用玻璃匀浆器匀浆,直至充分裂解。充分裂解后,离心,取上清获得各组织总蛋白。用BCA蛋白浓度测定试剂盒测浓度。各取20μg总蛋白,用10%的SDS-PAGE凝胶,100V,30min;120V,1.5h进行电泳。电泳完毕后利用Bio-Rad湿转转膜仪350mA,转膜80min。转膜完成后,用5%脱脂奶粉封闭2h,然后加入Cas9一抗(1:1000稀释)进行孵育过夜,TBST洗膜3x10min,然后HRP标记的羊抗兔二抗(1:1000稀释)孵育2h,TBST洗膜3x10min,最后进行BCL显色。结果显示(见图4),克隆猪新生一、三、四、五、七、八号仔猪体内成功表达Cas9蛋白。
实施例5抗ASFV克隆猪攻毒试验
以“接触式”感染模式进行病毒感染试验,将所有猪随机分配到两个单独的房间中,每个房间包括一只将被用作传染源的健康商品猪,三只抗ASFV克隆猪和三只健康商品猪。适应一周后对传染源猪注射ASFV毒株(Pig/HLJ/18),而其他笼养猪没有被注射,因此可以模拟CSFV通过同居自然传播。在感染过程中,监测猪只相关临床症状(包括呼吸困难、发热、心跳加快、眼、鼻处有浆液性或粘液性脓性分泌物和皮肤发绀等)并解剖死亡猪只观察病理变化。结果显示:传染源猪于接种病毒后第3天死亡,健康商品猪于第3-7内死亡,抗ASFV克隆猪无死亡。病死猪临床症状不明显,仅出现发热症状,剖检一般表现为急性出血性变化,部分脾脏极度肿大,难以与其他急性出血性疾病区别。抗ASFV克隆猪于第3-5天出现发热症状且采食减少体重增加缓慢,随后症状逐渐减轻,直至恢复正常。结果显示本发明获得的抗ASFV克隆猪的pRosa26基因第1内含子被成功敲入针对病毒蛋白pE248R基因的sgRNA-Cas9,同时能够稳定表达该sgRNA-Cas9,该ASFV克隆猪具有良好的抗ASFV能力。
以上所述的实施例仅是对本发明的优选方式进行描述,并非对本发明的范围进行限定,在不脱离本发明设计精神的前提下,本领域普通技术人员对本发明的技术方案做出的各种变形和改进,均应落入本发明权利要求书确定的保护范围内。
序列表
<110> 广东海洋大学
<120> 一种抗非洲猪瘟克隆猪的制备方法
<160> 16
<170> SIPOSequenceListing 1.0
<210> 1
<211> 172
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
acaaaaagca caaaagagta agtggacaac tgcttctaga ccaaccaagg gttttagttg 60
ccatttataa acactgggag aaaatacaaa tgctactcaa atatccccaa gtctatttaa 120
aatagtccta aagttgccac aggctgagtt tctgagctaa tgtagagcac ct 172
<210> 2
<211> 5394
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgttagagag 60
ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120
aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 180
atgcttaccg taacttgaaa gtatttcgat ttcttggctt tatatatctt gtggaaagga 240
cgaaacaccg tacataggcg tattcggtga gttttagagc tagaaatagc aagttaaaat 300
aaggctagtc cgttatcaac ttgaaaaagt ggcaccgagt cggtgctttt ttgttttaga 360
gctagaaata gcaagttaaa ataaggctag tccgttttta gcgcgtgcgc caattctgca 420
gacaaatggc tctagaggta ccgacattga ttattgacta gttattaata gtaatcaatt 480
acggggtcat tagttcatag cccatatatg gagttccgcg ttacataact tacggtaaat 540
ggcccgcctg gctgaccgcc caacgacccc cgcccattga cgtcaataat gacgtatgtt 600
cccatagtaa cgccaatagg gactttccat tgacgtcaat gggtggagta tttacggtaa 660
actgcccact tggcagtaca tcaagtgtat catatgccaa gtccgccccc tattgacgtc 720
aatgacggta aatggcccgc ctggcattat gcccagtaca tgaccttacg ggactttcct 780
acttggcagt acatctacgt attagtcatc gctattacca tggtgatgcg gttttggcag 840
tacaccaatg ggcgtggata gcggtttgac tcacggggat ttccaagtct ccaccccatt 900
gacgtcaatg ggagtttgtt ttggcaccaa aatcaacggg actttccaaa atgtcgtaat 960
aaccccgccc cgttgacgca aatgggcggt aggcgtgtac ggtgggaggt ctatataagc 1020
agagctgtga tgcggttttg gcagtacacc aatgggcgtg acaagaagta cagcatcggc 1080
ctggacatcg gcaccaactc tgtgggctgg gccgtgatca ccgacgagta caaggtgccc 1140
agcaagaaat tcaaggtgct gggcaacacc gaccggcaca gcatcaagaa gaacctgatc 1200
ggagccctgc tgttcgacag cggcgaaaca gccgaggcca cccggctgaa gagaaccgcc 1260
agaagaagat acaccagacg gaagaaccgg atctgctatc tgcaagagat cttcagcaac 1320
gagatggcca aggtggacga cagcttcttc cacagactgg aagagtcctt cctggtggaa 1380
gaggataaga agcacgagcg gcaccccatc ttcggcaaca tcgtggacga ggtggcctac 1440
cacgagaagt accccaccat ctaccacctg agaaagaaac tggtggacag caccgacaag 1500
gccgacctgc ggctgatcta tctggccctg gcccacatga tcaagttccg gggccacttc 1560
ctgatcgagg gcgacctgaa ccccgacaac agcgacgtgg acaagctgtt catccagctg 1620
gtgcagacct acaaccagct gttcgaggaa aaccccatca acgccagcgg cgtggacgcc 1680
aaggccatcc tgtctgccag actgagcaag agcagacggc tggaaaatct gatcgcccag 1740
ctgcccggcg agaagaagaa tggcctgttc ggaaacctga ttgccctgag cctgggcctg 1800
acccccaact tcaagagcaa cttcgacctg gccgaggatg ccaaactgca gctgagcaag 1860
gacacctacg acgacgacct ggacaacctg ctggcccaga tcggcgacca gtacgccgac 1920
ctgtttctgg ccgccaagaa cctgtccgac gccatcctgc tgagcgacat cctgagagtg 1980
aacaccgaga tcaccaaggc ccccctgagc gcctctatga tcaagagata cgacgagcac 2040
caccaggacc tgaccctgct gaaagctctc gtgcggcagc agctgcctga gaagtacaaa 2100
gagattttct tcgaccagag caagaacggc tacgccggct acattgacgg cggagccagc 2160
caggaagagt tctacaagtt catcaagccc atcctggaaa agatggacgg caccgaggaa 2220
ctgctcgtga agctgaacag agaggacctg ctgcggaagc agcggacctt cgacaacggc 2280
agcatccccc accagatcca cctgggagag ctgcacgcca ttctgcggcg gcaggaagat 2340
ttttacccat tcctgaagga caaccgggaa aagatcgaga agatcctgac cttccgcatc 2400
ccctactacg tgggccctct ggccagggga aacagcagat tcgcctggat gaccagaaag 2460
agcgaggaaa ccatcacccc ctggaacttc gaggaagtgg tggacaaggg cgcttccgcc 2520
cagagcttca tcgagcggat gaccaacttc gataagaacc tgcccaacga gaaggtgctg 2580
cccaagcaca gcctgctgta cgagtacttc accgtgtata acgagctgac caaagtgaaa 2640
tacgtgaccg agggaatgag aaagcccgcc ttcctgagcg gcgagcagaa aaaggccatc 2700
gtggacctgc tgttcaagac caaccggaaa gtgaccgtga agcagctgaa agaggactac 2760
ttcaagaaaa tcgagtgctt cgactccgtg gaaatctccg gcgtggaaga tcggttcaac 2820
gcctccctgg gcacatacca cgatctgctg aaaattatca aggacaagga cttcctggac 2880
aatgaggaaa acgaggacat tctggaagat atcgtgctga ccctgacact gtttgaggac 2940
agagagatga tcgaggaacg gctgaaaacc tatgcccacc tgttcgacga caaagtgatg 3000
aagcagctga agcggcggag atacaccggc tggggcaggc tgagccggaa gctgatcaac 3060
ggcatccggg acaagcagtc cggcaagaca atcctggatt tcctgaagtc cgacggcttc 3120
gccaacagaa acttcatgca gctgatccac gacgacagcc tgacctttaa agaggacatc 3180
cagaaagccc aggtgtccgg ccagggcgat agcctgcacg agcacattgc caatctggcc 3240
ggcagccccg ccattaagaa gggcatcctg cagacagtga aggtggtgga cgagctcgtg 3300
aaagtgatgg gccggcacaa gcccgagaac atcgtgatcg aaatggccag agagaaccag 3360
accacccaga agggacagaa gaacagccgc gagagaatga agcggatcga agagggcatc 3420
aaagagctgg gcagccagat cctgaaagaa caccccgtgg aaaacaccca gctgcagaac 3480
gagaagctgt acctgtacta cctgcagaat gggcgggata tgtacgtgga ccaggaactg 3540
gacatcaacc ggctgtccga ctacgatgtg gaccatatcg tgcctcagag ctttctgaag 3600
gacgactcca tcgacaacaa ggtgctgacc agaagcgaca agaaccgggg caagagcgac 3660
aacgtgccct ccgaagaggt cgtgaagaag atgaagaact actggcggca gctgctgaac 3720
gccaagctga ttacccagag aaagttcgac aatctgacca aggccgagag aggcggcctg 3780
agcgaactgg ataaggccgg cttcatcaag agacagctgg tggaaacccg gcagatcaca 3840
aagcacgtgg cacagatcct ggactcccgg atgaacacta agtacgacga gaatgacaag 3900
ctgatccggg aagtgaaagt gatcaccctg aagtccaagc tggtgtccga tttccggaag 3960
gatttccagt tttacaaagt gcgcgagatc aacaactacc accacgccca cgacgcctac 4020
ctgaacgccg tcgtgggaac cgccctgatc aaaaagtacc ctaagctgga aagcgagttc 4080
gtgtacggcg actacaaggt gtacgacgtg cggaagatga tcgccaagag cgagcaggaa 4140
atcggcaagg ctaccgccaa gtacttcttc tacagcaaca tcatgaactt tttcaagacc 4200
gagattaccc tggccaacgg cgagatccgg aagcggcctc tgatcgagac aaacggcgaa 4260
accggggaga tcgtgtggga taagggccgg gattttgcca ccgtgcggaa agtgctgagc 4320
atgccccaag tgaatatcgt gaaaaagacc gaggtgcaga caggcggctt cagcaaagag 4380
tctatcctgc ccaagaggaa cagcgataag ctgatcgcca gaaagaagga ctgggaccct 4440
aagaagtacg gcggcttcga cagccccacc gtggcctatt ctgtgctggt ggtggccaaa 4500
gtggaaaagg gcaagtccaa gaaactgaag agtgtgaaag agctgctggg gatcaccatc 4560
atggaaagaa gcagcttcga gaagaatccc atcgactttc tggaagccaa gggctacaaa 4620
gaagtgaaaa aggacctgat catcaagctg cctaagtact ccctgttcga gctggaaaac 4680
ggccggaaga gaatgctggc ctctgccggc gaactgcaga agggaaacga actggccctg 4740
ccctccaaat atgtgaactt cctgtacctg gccagccact atgagaagct gaagggctcc 4800
cccgaggata atgagcagaa acagctgttt gtggaacagc acaagcacta cctggacgag 4860
atcatcgagc agatcagcga gttctccaag agagtgatcc tggccgacgc taatctggac 4920
aaagtgctgt ccgcctacaa caagcaccgg gataagccca tcagagagca ggccgagaat 4980
atcatccacc tgtttaccct gaccaatctg ggagcccctg ccgccttcaa gtactttgac 5040
accaccatcg accggaagag gtacaccagc accaaagagg tgctggacgc caccctgatc 5100
caccagagca tcaccggcct gtacgagaca cggatcgacc tgtctcagct gggaggcgac 5160
aactagagct cgctgatcag cctcgactgt gccttctagt tgccagccat ctgttgtttg 5220
cccctccccc gtgccttcct tgaccctgga aggtgccact cccactgtcc tttcctaata 5280
aaatgaggaa attgcatcgc attgtctgag taggtgtcat tctattctgg ggggtggggt 5340
ggggcaggac agcaaggggg aggattggga agagaatagc aggcatgctg ggga 5394
<210> 3
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
gagggcctat ttcccatgat 20
<210> 4
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 4
ttatcgtccg tacgacccct 20
<210> 5
<211> 3780
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 5
atgccgcggg aagcggccct agaaaagaca aaaaaaaaaa aaaaaaaaaa aaaatccagc 60
tgttttgtac ttaggcatta tattaaggcg gactgaattg cagaaatata aaacgtcact 120
cttatttgaa aaatacagtt acttccgtga aaatgttaat gtgatttatt tgtcactatg 180
tttttttccc ctcagtttta atttctagta tggtaaaata ctggtaaaca aagcatttgg 240
gaccctcagc ttttaataat gtgaagatat cctgagacca agaagttgga ggaagctgct 300
aagcatagtg agtatacatg gtaaacactc aaatgcctgt tgaatagctg gatgtagtga 360
aaaatgactc caggtattaa gcctggatta ctgggagggt gggcatgcca ggacagggag 420
cagattttaa tggagaaaga taggttcaag ttgagtttta agtaggacag gcaggggtaa 480
tcacaggagg cagctggaaa ttcagaattt gggcttgaga aaactaaaat accatgtttt 540
cctttccagt gaaaattgct ttcatcatag actatatgat tgaatagcta caatcccaca 600
gctgattagc atacatgttt gccttggggc agaagtatga gggtgacaaa gcaggcttct 660
cataagcaat ggtaaatttt ttcacattgt gcacattaaa aaatgcagta taggagagag 720
ctgtctatat ggtgttcctc ttcaacttaa aaataaataa ataaccaagg tacagtattt 780
caattttttt ttgtgtccta gaattttcaa actttcatca tattcccaca taatacctca 840
tctgaacttc atggaaaggg ctactttttc tatgcctagc tcagtagtat taaggccttt 900
tgggctttat tgtaatttat gtactttaca gatttaaacc cctgcccccg gctgcgccca 960
tggcatgtgg aaattcctga gctggggatt agaacctatg ccacaattgt agcctgcacc 1020
acagctgtgg caaggccaca tccttaacct gctatgccaa gggagctttc aatataaaac 1080
ttttaaacca cctccttttt ttcagtctta gtcttatcct ttggcacttg caatggagac 1140
ctgagtgcat ctggcattga tacagaacct ctaaagtttt ctgaaagtct tgttacaatg 1200
tttaaaaatg tttccctctc taggcactag tacactgaca gtcactggaa gataaatgac 1260
tttcctttcc tttcattaaa attatatttg tctcagtgtc tttttttccc ccctctaaaa 1320
tatattgaat gtctggtcca taactcagtc attttgtgtc cagattattt tatttatttt 1380
aatggccaca cccctggcat atggaagttc ctgggccagg gactgaatcc cagctgcagc 1440
tgcagcaatg ctggatcctt ttaacccact acacagggct ggtgattgaa cccatgcctt 1500
tgcagcaacc tgagctgctg tggatggatt ctaacccact gtgccatggc aggaattgtg 1560
tgttcagatt attaaaatta tcttaaccat ctttttataa tcccatgatg caggaagccc 1620
acttcagaag ttaaccaagg tcacacaact ggtaggtacc tggcagtatc gtatagaatc 1680
tcagtttttc tgaatcctca tataatgcat tttctgtcaa cagataacaa aatattgggg 1740
tggggggaga tggcaaattt ttgcagacat tgttcactac atacttaatc tgaaatcaat 1800
ctgttcatgt ttttgggcct ttagctatga tggaccaagc ataaaaaaca gccattatgc 1860
aaaaatatcc atttgttcaa ccaatattaa atactcatga taggtttttt tttctttttt 1920
cttttttttt ttttttcttt ctttttgcca tttcttgggc cgctcctgcg gcatatgaag 1980
gttcccaggc taggggtcga atcagagctg tagccatcgg cctacgccag aaccacagca 2040
acttgggatc cgagccgtgt ctgcaaccta caccacagct cagggcaatg ccagatcctt 2100
aacccactga gcaagatcag ggattgaacc tgcaacctca ttgttcctcg tcggatttgc 2160
taacctctga gccatgacag gaactccgct ggtaggtact ttttatcagg taaacagtgg 2220
agaaaacaga taaggtcctt gtacttttcc agttctgtgt tctggtgacc agaggtttat 2280
atatatagtt tcttttgtaa acagctttaa tgttgaaccc cataatcaac tgtgcattct 2340
gatgatggta aaaactccag tctgggatat aagagcctta taagtccttc tttccagttc 2400
attctcatac ctctgggagg tagtatatca gagaggaacc agactaggac tgttggctgt 2460
gctgctaatg tgaattctgt tctttcaaag ggaagaagtc ctatgtcctt ttctaaatga 2520
gacgtccaaa gttaacatga ataggagttt tggctgtggc gcagtgggtt aatgatttgg 2580
cttgtctctg gcagtgccag ttctacccct ggcccagaaa catccatatg ccacggtgca 2640
gccaaaaaag gggagaaaac aagttgatat gagtagcact attatgttat taacatgaca 2700
ctgaacatct aagctgaatg cagccaaaaa caatactact atacagaatt ccacacaaga 2760
tcccaacttc tcttagtccc agggaggtgt ttaggttatt tcaattccta ctgttagcaa 2820
agactttctg caacaggaaa agcaactaag gatgaatagt gaccaagagt aaacaagaat 2880
ttacatgaag tttttaattc aaagacatca gttctctagt aaagaagccc aaacatcacc 2940
acctttctgt actgaatgaa aaataaaatt tctttaaata tggcttgttg gtcgcatact 3000
tcatctacaa ggctctttgc ttctatttac aaatagaaat gtctatttag ttctatgtat 3060
taatctgaat aacaggtaca tattatgatt tttaaggcag atggtaaact ttcccataga 3120
tcttaggaga tttgatcttg tcgtggggca agcactgttt tacagtgctt cattttttta 3180
aaggtcaggt aaagaacctg accaactaaa tatcaaagct gtatgggcaa tgaaatgtaa 3240
cctcatcctc tgattaaact ctgcctttca attaggctag ggtagctttc cacctgctac 3300
agtgctataa agcctgaaaa tgtttaaatg tttaaatcca agtaccagag cattttagta 3360
ggcttagcat taaagcattt taagaaaagt acttattgcc caactactcc ttcaaaacag 3420
ttccacagca aagttgtgct ttctcataag acattccacg ccattcacct tttgctaatt 3480
gggtgaagag cttttccaaa gtacaccttt attaatacta tttttccctc aaaataagtt 3540
cttcatgtgg acatttctag tgtcaggaag cataaaaact tcattctttg cattaccaag 3600
gagatcttcc tccatcttgt tctgaaggat gaacaaaagt ttgaggtgta cgtttcagaa 3660
gataaactgc agcatgaagt ccccctatgt tcacccagac agtatgcacc ttccgccata 3720
catgtcccat tgcggataat gcctgtgtaa acacaaaaag cacaaaagag taagtggaca 3780
<210> 6
<211> 24
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 6
atgccgcggg aagcggccct agaa 24
<210> 7
<211> 24
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 7
tttcgtgttt tctcattcac ctgt 24
<210> 8
<211> 1935
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 8
gggttttagt tgccatttat aaacactggg agaaaataca aatgctactc aaatatcccc 60
aagtctattt aaaatagtcc taaagttgcc acaggctgag tttctgagct aatgtagagc 120
accttagtaa agcacttctt gtcctgagtc agtagtacag ctcggcctgt ccctggtcta 180
cagacacggc tcatctcccg taggcaagct ggataaaggt cccagtttct cttcttggaa 240
cccatcctat aaaagaagat gtggtgagtc actattgtag attagtatca aggactatat 300
gaaatgagtc attaaaatct cattgcagta agaatacctg aggtaagaaa aacatttgtt 360
ttttagaagc cagagctctg ccattacttg tcagtgaaat gagtgatcag acttagttaa 420
actgcttaga attttgaata gaatgcatca gttatgtgag aaaaaaaatt aatagttgtc 480
ctcttagtat aagcagtcaa attaaccaat gattaaaaag catttatcct gaaaaataac 540
caagtcttta tcaatctctg aagtattatt atgttctatt attattatgt tctattctag 600
cccaacaatg ggctagaaag tggatgaatc tgtgatggcc aggatcaaaa tggagttaac 660
acattcctga gttctcagaa gaaaccgaat tggtgaatcc acaattcttg agtgaaaaac 720
ttgttgagtc tactaaaaga aatggaagat ttctgacaga ataagctcaa tgcaacagat 780
ttaaaagaca agtgggtact aacactaata taacttgtta gtgaaggtaa aattcatttt 840
taaaaggacc aactcccacc tttttccaaa tggcatgtct gttacaataa tgtccacaga 900
accagttctt aatggcagtt tgcagatatc ccattgaaca gtatctatgg gcaagcccca 960
ggacaatttg ctgtggggac aaaagaaagg ggcttcagca tctgaacaat gaattttgta 1020
gactgctaca aaatataaaa ggtaaaataa tagtgacatc agtaacattt aaagtagcac 1080
gtaggtggaa aggataagtc aaagttttca taatgacaat ccgtaagaat gacaaaattt 1140
ttttttttgg tcttttcagg gccgcatcca cagcacatgg agggtcccag gccaggggtt 1200
aaactggagc tgtagctgct ggcctactcc acagccacag cgacgcagga tcccaagtgt 1260
agtctgtgac ctacaccaca gctcatggca atgccagatc tttaacccac tgagagaggc 1320
cagggatcaa acctgcttcc ttatgggtgc tagtcaaatt tgtttccact gagccacgat 1380
gagaactcca agaatgacaa atttaaaaat tagttaagat tgatttataa aagatatcta 1440
tatctgtttc atctacaaga aaacagatta aggggaagag aatgtgacaa aataactgta 1500
atttgaaaat agcgttcagg cagtaaataa ctgatgatgt aacactgttg atgaatctga 1560
tgtactggaa aaaaacaaca ctaaagagta aaaacgtgat gaatggacat ctgaaggata 1620
aactttaagt ctacgtagta agaacaggaa acctaaagaa acaaatatgc aaaattagga 1680
aatataaacg tactagtctt aatattaaaa cacatatacc atactattaa aaaaaacaag 1740
gcaaagaaca aagttaagat aaaaaaatgg atgatataag acaaaattaa caataaatat 1800
aaatgattta aatccttcca attaagcaaa gctactagtt taagggagtt tcctggtagc 1860
ctacaaggtt aaggacctag cgttatcact gctgtgttgg tttgatccct ggcccaggaa 1920
cttttgcatg ctgca 1935
<210> 9
<211> 25
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 9
tgtttataaa tggcaactaa aaccc 25
<210> 10
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 10
cccaggaact tttgcatgct gca 23
<210> 11
<211> 11109
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 11
atgccgcggg aagcggccct agaaaagaca aaaaaaaaaa aaaaaaaaaa aaaatccagc 60
tgttttgtac ttaggcatta tattaaggcg gactgaattg cagaaatata aaacgtcact 120
cttatttgaa aaatacagtt acttccgtga aaatgttaat gtgatttatt tgtcactatg 180
tttttttccc ctcagtttta atttctagta tggtaaaata ctggtaaaca aagcatttgg 240
gaccctcagc ttttaataat gtgaagatat cctgagacca agaagttgga ggaagctgct 300
aagcatagtg agtatacatg gtaaacactc aaatgcctgt tgaatagctg gatgtagtga 360
aaaatgactc caggtattaa gcctggatta ctgggagggt gggcatgcca ggacagggag 420
cagattttaa tggagaaaga taggttcaag ttgagtttta agtaggacag gcaggggtaa 480
tcacaggagg cagctggaaa ttcagaattt gggcttgaga aaactaaaat accatgtttt 540
cctttccagt gaaaattgct ttcatcatag actatatgat tgaatagcta caatcccaca 600
gctgattagc atacatgttt gccttggggc agaagtatga gggtgacaaa gcaggcttct 660
cataagcaat ggtaaatttt ttcacattgt gcacattaaa aaatgcagta taggagagag 720
ctgtctatat ggtgttcctc ttcaacttaa aaataaataa ataaccaagg tacagtattt 780
caattttttt ttgtgtccta gaattttcaa actttcatca tattcccaca taatacctca 840
tctgaacttc atggaaaggg ctactttttc tatgcctagc tcagtagtat taaggccttt 900
tgggctttat tgtaatttat gtactttaca gatttaaacc cctgcccccg gctgcgccca 960
tggcatgtgg aaattcctga gctggggatt agaacctatg ccacaattgt agcctgcacc 1020
acagctgtgg caaggccaca tccttaacct gctatgccaa gggagctttc aatataaaac 1080
ttttaaacca cctccttttt ttcagtctta gtcttatcct ttggcacttg caatggagac 1140
ctgagtgcat ctggcattga tacagaacct ctaaagtttt ctgaaagtct tgttacaatg 1200
tttaaaaatg tttccctctc taggcactag tacactgaca gtcactggaa gataaatgac 1260
tttcctttcc tttcattaaa attatatttg tctcagtgtc tttttttccc ccctctaaaa 1320
tatattgaat gtctggtcca taactcagtc attttgtgtc cagattattt tatttatttt 1380
aatggccaca cccctggcat atggaagttc ctgggccagg gactgaatcc cagctgcagc 1440
tgcagcaatg ctggatcctt ttaacccact acacagggct ggtgattgaa cccatgcctt 1500
tgcagcaacc tgagctgctg tggatggatt ctaacccact gtgccatggc aggaattgtg 1560
tgttcagatt attaaaatta tcttaaccat ctttttataa tcccatgatg caggaagccc 1620
acttcagaag ttaaccaagg tcacacaact ggtaggtacc tggcagtatc gtatagaatc 1680
tcagtttttc tgaatcctca tataatgcat tttctgtcaa cagataacaa aatattgggg 1740
tggggggaga tggcaaattt ttgcagacat tgttcactac atacttaatc tgaaatcaat 1800
ctgttcatgt ttttgggcct ttagctatga tggaccaagc ataaaaaaca gccattatgc 1860
aaaaatatcc atttgttcaa ccaatattaa atactcatga taggtttttt tttctttttt 1920
cttttttttt ttttttcttt ctttttgcca tttcttgggc cgctcctgcg gcatatgaag 1980
gttcccaggc taggggtcga atcagagctg tagccatcgg cctacgccag aaccacagca 2040
acttgggatc cgagccgtgt ctgcaaccta caccacagct cagggcaatg ccagatcctt 2100
aacccactga gcaagatcag ggattgaacc tgcaacctca ttgttcctcg tcggatttgc 2160
taacctctga gccatgacag gaactccgct ggtaggtact ttttatcagg taaacagtgg 2220
agaaaacaga taaggtcctt gtacttttcc agttctgtgt tctggtgacc agaggtttat 2280
atatatagtt tcttttgtaa acagctttaa tgttgaaccc cataatcaac tgtgcattct 2340
gatgatggta aaaactccag tctgggatat aagagcctta taagtccttc tttccagttc 2400
attctcatac ctctgggagg tagtatatca gagaggaacc agactaggac tgttggctgt 2460
gctgctaatg tgaattctgt tctttcaaag ggaagaagtc ctatgtcctt ttctaaatga 2520
gacgtccaaa gttaacatga ataggagttt tggctgtggc gcagtgggtt aatgatttgg 2580
cttgtctctg gcagtgccag ttctacccct ggcccagaaa catccatatg ccacggtgca 2640
gccaaaaaag gggagaaaac aagttgatat gagtagcact attatgttat taacatgaca 2700
ctgaacatct aagctgaatg cagccaaaaa caatactact atacagaatt ccacacaaga 2760
tcccaacttc tcttagtccc agggaggtgt ttaggttatt tcaattccta ctgttagcaa 2820
agactttctg caacaggaaa agcaactaag gatgaatagt gaccaagagt aaacaagaat 2880
ttacatgaag tttttaattc aaagacatca gttctctagt aaagaagccc aaacatcacc 2940
acctttctgt actgaatgaa aaataaaatt tctttaaata tggcttgttg gtcgcatact 3000
tcatctacaa ggctctttgc ttctatttac aaatagaaat gtctatttag ttctatgtat 3060
taatctgaat aacaggtaca tattatgatt tttaaggcag atggtaaact ttcccataga 3120
tcttaggaga tttgatcttg tcgtggggca agcactgttt tacagtgctt cattttttta 3180
aaggtcaggt aaagaacctg accaactaaa tatcaaagct gtatgggcaa tgaaatgtaa 3240
cctcatcctc tgattaaact ctgcctttca attaggctag ggtagctttc cacctgctac 3300
agtgctataa agcctgaaaa tgtttaaatg tttaaatcca agtaccagag cattttagta 3360
ggcttagcat taaagcattt taagaaaagt acttattgcc caactactcc ttcaaaacag 3420
ttccacagca aagttgtgct ttctcataag acattccacg ccattcacct tttgctaatt 3480
gggtgaagag cttttccaaa gtacaccttt attaatacta tttttccctc aaaataagtt 3540
cttcatgtgg acatttctag tgtcaggaag cataaaaact tcattctttg cattaccaag 3600
gagatcttcc tccatcttgt tctgaaggat gaacaaaagt ttgaggtgta cgtttcagaa 3660
gataaactgc agcatgaagt ccccctatgt tcacccagac agtatgcacc ttccgccata 3720
catgtcccat tgcggataat gcctgtgtaa acacaaaaag cacaaaagag taagtggaca 3780
gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgttagagag 3840
ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 3900
aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 3960
atgcttaccg taacttgaaa gtatttcgat ttcttggctt tatatatctt gtggaaagga 4020
cgaaacaccg tacataggcg tattcggtga gttttagagc tagaaatagc aagttaaaat 4080
aaggctagtc cgttatcaac ttgaaaaagt ggcaccgagt cggtgctttt ttgttttaga 4140
gctagaaata gcaagttaaa ataaggctag tccgttttta gcgcgtgcgc caattctgca 4200
gacaaatggc tctagaggta ccgacattga ttattgacta gttattaata gtaatcaatt 4260
acggggtcat tagttcatag cccatatatg gagttccgcg ttacataact tacggtaaat 4320
ggcccgcctg gctgaccgcc caacgacccc cgcccattga cgtcaataat gacgtatgtt 4380
cccatagtaa cgccaatagg gactttccat tgacgtcaat gggtggagta tttacggtaa 4440
actgcccact tggcagtaca tcaagtgtat catatgccaa gtccgccccc tattgacgtc 4500
aatgacggta aatggcccgc ctggcattat gcccagtaca tgaccttacg ggactttcct 4560
acttggcagt acatctacgt attagtcatc gctattacca tggtgatgcg gttttggcag 4620
tacaccaatg ggcgtggata gcggtttgac tcacggggat ttccaagtct ccaccccatt 4680
gacgtcaatg ggagtttgtt ttggcaccaa aatcaacggg actttccaaa atgtcgtaat 4740
aaccccgccc cgttgacgca aatgggcggt aggcgtgtac ggtgggaggt ctatataagc 4800
agagctgtga tgcggttttg gcagtacacc aatgggcgtg acaagaagta cagcatcggc 4860
ctggacatcg gcaccaactc tgtgggctgg gccgtgatca ccgacgagta caaggtgccc 4920
agcaagaaat tcaaggtgct gggcaacacc gaccggcaca gcatcaagaa gaacctgatc 4980
ggagccctgc tgttcgacag cggcgaaaca gccgaggcca cccggctgaa gagaaccgcc 5040
agaagaagat acaccagacg gaagaaccgg atctgctatc tgcaagagat cttcagcaac 5100
gagatggcca aggtggacga cagcttcttc cacagactgg aagagtcctt cctggtggaa 5160
gaggataaga agcacgagcg gcaccccatc ttcggcaaca tcgtggacga ggtggcctac 5220
cacgagaagt accccaccat ctaccacctg agaaagaaac tggtggacag caccgacaag 5280
gccgacctgc ggctgatcta tctggccctg gcccacatga tcaagttccg gggccacttc 5340
ctgatcgagg gcgacctgaa ccccgacaac agcgacgtgg acaagctgtt catccagctg 5400
gtgcagacct acaaccagct gttcgaggaa aaccccatca acgccagcgg cgtggacgcc 5460
aaggccatcc tgtctgccag actgagcaag agcagacggc tggaaaatct gatcgcccag 5520
ctgcccggcg agaagaagaa tggcctgttc ggaaacctga ttgccctgag cctgggcctg 5580
acccccaact tcaagagcaa cttcgacctg gccgaggatg ccaaactgca gctgagcaag 5640
gacacctacg acgacgacct ggacaacctg ctggcccaga tcggcgacca gtacgccgac 5700
ctgtttctgg ccgccaagaa cctgtccgac gccatcctgc tgagcgacat cctgagagtg 5760
aacaccgaga tcaccaaggc ccccctgagc gcctctatga tcaagagata cgacgagcac 5820
caccaggacc tgaccctgct gaaagctctc gtgcggcagc agctgcctga gaagtacaaa 5880
gagattttct tcgaccagag caagaacggc tacgccggct acattgacgg cggagccagc 5940
caggaagagt tctacaagtt catcaagccc atcctggaaa agatggacgg caccgaggaa 6000
ctgctcgtga agctgaacag agaggacctg ctgcggaagc agcggacctt cgacaacggc 6060
agcatccccc accagatcca cctgggagag ctgcacgcca ttctgcggcg gcaggaagat 6120
ttttacccat tcctgaagga caaccgggaa aagatcgaga agatcctgac cttccgcatc 6180
ccctactacg tgggccctct ggccagggga aacagcagat tcgcctggat gaccagaaag 6240
agcgaggaaa ccatcacccc ctggaacttc gaggaagtgg tggacaaggg cgcttccgcc 6300
cagagcttca tcgagcggat gaccaacttc gataagaacc tgcccaacga gaaggtgctg 6360
cccaagcaca gcctgctgta cgagtacttc accgtgtata acgagctgac caaagtgaaa 6420
tacgtgaccg agggaatgag aaagcccgcc ttcctgagcg gcgagcagaa aaaggccatc 6480
gtggacctgc tgttcaagac caaccggaaa gtgaccgtga agcagctgaa agaggactac 6540
ttcaagaaaa tcgagtgctt cgactccgtg gaaatctccg gcgtggaaga tcggttcaac 6600
gcctccctgg gcacatacca cgatctgctg aaaattatca aggacaagga cttcctggac 6660
aatgaggaaa acgaggacat tctggaagat atcgtgctga ccctgacact gtttgaggac 6720
agagagatga tcgaggaacg gctgaaaacc tatgcccacc tgttcgacga caaagtgatg 6780
aagcagctga agcggcggag atacaccggc tggggcaggc tgagccggaa gctgatcaac 6840
ggcatccggg acaagcagtc cggcaagaca atcctggatt tcctgaagtc cgacggcttc 6900
gccaacagaa acttcatgca gctgatccac gacgacagcc tgacctttaa agaggacatc 6960
cagaaagccc aggtgtccgg ccagggcgat agcctgcacg agcacattgc caatctggcc 7020
ggcagccccg ccattaagaa gggcatcctg cagacagtga aggtggtgga cgagctcgtg 7080
aaagtgatgg gccggcacaa gcccgagaac atcgtgatcg aaatggccag agagaaccag 7140
accacccaga agggacagaa gaacagccgc gagagaatga agcggatcga agagggcatc 7200
aaagagctgg gcagccagat cctgaaagaa caccccgtgg aaaacaccca gctgcagaac 7260
gagaagctgt acctgtacta cctgcagaat gggcgggata tgtacgtgga ccaggaactg 7320
gacatcaacc ggctgtccga ctacgatgtg gaccatatcg tgcctcagag ctttctgaag 7380
gacgactcca tcgacaacaa ggtgctgacc agaagcgaca agaaccgggg caagagcgac 7440
aacgtgccct ccgaagaggt cgtgaagaag atgaagaact actggcggca gctgctgaac 7500
gccaagctga ttacccagag aaagttcgac aatctgacca aggccgagag aggcggcctg 7560
agcgaactgg ataaggccgg cttcatcaag agacagctgg tggaaacccg gcagatcaca 7620
aagcacgtgg cacagatcct ggactcccgg atgaacacta agtacgacga gaatgacaag 7680
ctgatccggg aagtgaaagt gatcaccctg aagtccaagc tggtgtccga tttccggaag 7740
gatttccagt tttacaaagt gcgcgagatc aacaactacc accacgccca cgacgcctac 7800
ctgaacgccg tcgtgggaac cgccctgatc aaaaagtacc ctaagctgga aagcgagttc 7860
gtgtacggcg actacaaggt gtacgacgtg cggaagatga tcgccaagag cgagcaggaa 7920
atcggcaagg ctaccgccaa gtacttcttc tacagcaaca tcatgaactt tttcaagacc 7980
gagattaccc tggccaacgg cgagatccgg aagcggcctc tgatcgagac aaacggcgaa 8040
accggggaga tcgtgtggga taagggccgg gattttgcca ccgtgcggaa agtgctgagc 8100
atgccccaag tgaatatcgt gaaaaagacc gaggtgcaga caggcggctt cagcaaagag 8160
tctatcctgc ccaagaggaa cagcgataag ctgatcgcca gaaagaagga ctgggaccct 8220
aagaagtacg gcggcttcga cagccccacc gtggcctatt ctgtgctggt ggtggccaaa 8280
gtggaaaagg gcaagtccaa gaaactgaag agtgtgaaag agctgctggg gatcaccatc 8340
atggaaagaa gcagcttcga gaagaatccc atcgactttc tggaagccaa gggctacaaa 8400
gaagtgaaaa aggacctgat catcaagctg cctaagtact ccctgttcga gctggaaaac 8460
ggccggaaga gaatgctggc ctctgccggc gaactgcaga agggaaacga actggccctg 8520
ccctccaaat atgtgaactt cctgtacctg gccagccact atgagaagct gaagggctcc 8580
cccgaggata atgagcagaa acagctgttt gtggaacagc acaagcacta cctggacgag 8640
atcatcgagc agatcagcga gttctccaag agagtgatcc tggccgacgc taatctggac 8700
aaagtgctgt ccgcctacaa caagcaccgg gataagccca tcagagagca ggccgagaat 8760
atcatccacc tgtttaccct gaccaatctg ggagcccctg ccgccttcaa gtactttgac 8820
accaccatcg accggaagag gtacaccagc accaaagagg tgctggacgc caccctgatc 8880
caccagagca tcaccggcct gtacgagaca cggatcgacc tgtctcagct gggaggcgac 8940
aactagagct cgctgatcag cctcgactgt gccttctagt tgccagccat ctgttgtttg 9000
cccctccccc gtgccttcct tgaccctgga aggtgccact cccactgtcc tttcctaata 9060
aaatgaggaa attgcatcgc attgtctgag taggtgtcat tctattctgg ggggtggggt 9120
ggggcaggac agcaaggggg aggattggga agagaatagc aggcatgctg gggagggttt 9180
tagttgccat ttataaacac tgggagaaaa tacaaatgct actcaaatat ccccaagtct 9240
atttaaaata gtcctaaagt tgccacaggc tgagtttctg agctaatgta gagcacctta 9300
gtaaagcact tcttgtcctg agtcagtagt acagctcggc ctgtccctgg tctacagaca 9360
cggctcatct cccgtaggca agctggataa aggtcccagt ttctcttctt ggaacccatc 9420
ctataaaaga agatgtggtg agtcactatt gtagattagt atcaaggact atatgaaatg 9480
agtcattaaa atctcattgc agtaagaata cctgaggtaa gaaaaacatt tgttttttag 9540
aagccagagc tctgccatta cttgtcagtg aaatgagtga tcagacttag ttaaactgct 9600
tagaattttg aatagaatgc atcagttatg tgagaaaaaa aattaatagt tgtcctctta 9660
gtataagcag tcaaattaac caatgattaa aaagcattta tcctgaaaaa taaccaagtc 9720
tttatcaatc tctgaagtat tattatgttc tattattatt atgttctatt ctagcccaac 9780
aatgggctag aaagtggatg aatctgtgat ggccaggatc aaaatggagt taacacattc 9840
ctgagttctc agaagaaacc gaattggtga atccacaatt cttgagtgaa aaacttgttg 9900
agtctactaa aagaaatgga agatttctga cagaataagc tcaatgcaac agatttaaaa 9960
gacaagtggg tactaacact aatataactt gttagtgaag gtaaaattca tttttaaaag 10020
gaccaactcc cacctttttc caaatggcat gtctgttaca ataatgtcca cagaaccagt 10080
tcttaatggc agtttgcaga tatcccattg aacagtatct atgggcaagc cccaggacaa 10140
tttgctgtgg ggacaaaaga aaggggcttc agcatctgaa caatgaattt tgtagactgc 10200
tacaaaatat aaaaggtaaa ataatagtga catcagtaac atttaaagta gcacgtaggt 10260
ggaaaggata agtcaaagtt ttcataatga caatccgtaa gaatgacaaa attttttttt 10320
ttggtctttt cagggccgca tccacagcac atggagggtc ccaggccagg ggttaaactg 10380
gagctgtagc tgctggccta ctccacagcc acagcgacgc aggatcccaa gtgtagtctg 10440
tgacctacac cacagctcat ggcaatgcca gatctttaac ccactgagag aggccaggga 10500
tcaaacctgc ttccttatgg gtgctagtca aatttgtttc cactgagcca cgatgagaac 10560
tccaagaatg acaaatttaa aaattagtta agattgattt ataaaagata tctatatctg 10620
tttcatctac aagaaaacag attaagggga agagaatgtg acaaaataac tgtaatttga 10680
aaatagcgtt caggcagtaa ataactgatg atgtaacact gttgatgaat ctgatgtact 10740
ggaaaaaaac aacactaaag agtaaaaacg tgatgaatgg acatctgaag gataaacttt 10800
aagtctacgt agtaagaaca ggaaacctaa agaaacaaat atgcaaaatt aggaaatata 10860
aacgtactag tcttaatatt aaaacacata taccatacta ttaaaaaaaa caaggcaaag 10920
aacaaagtta agataaaaaa atggatgata taagacaaaa ttaacaataa atataaatga 10980
tttaaatcct tccaattaag caaagctact agtttaaggg agtttcctgg tagcctacaa 11040
ggttaaggac ctagcgttat cactgctgtg ttggtttgat ccctggccca ggaacttttg 11100
catgctgca 11109
<210> 12
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 12
actgcttcta gaccaaccaa 20
<210> 13
<211> 25
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 13
caccgactgc ttctagacca accaa 25
<210> 14
<211> 25
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 14
aaacttggtt ggtctagaag cagtc 25
<210> 15
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 15
tgtggacatt tctagtgtca gga 23
<210> 16
<211> 22
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 16
agtgactcac cacatcttct tt 22
Claims (9)
1.猪Rosa26基因donor载体,其特征在于,将猪Rosa26基因的第1内含子敲入表达靶向非洲猪瘟病毒pE248R基因的sgRNA-Cas9序列;所述猪Rosa26基因第1内含子的核苷酸序列如SEQ ID NO.1所示,所述表达靶向非洲猪瘟病毒pE248R基因的sgRNA-Cas9序列如SEQ IDNO.2所示。
2.一种权利要求1所述猪Rosa26基因donor载体的制备方法,其特征在于,具体制备方法包括:
S1.利用猪细胞基因组DNA为模板扩增出3780bp的猪Rosa26基因第1内含子同源左臂;将表达特异性靶向病毒pE248R基因的sgRNA-Cas9基因与猪Rosa26基因第1内含子同源左臂融合,得到融合片段1;
S2.利用猪细胞基因组DNA为模板扩增出1935bp的猪Rosa26基因第1内含子同源右臂;将融合片段1与猪Rosa26基因第1内含子同源右臂融合,得到融合片段2;
S3.用SacII和SphI限制性内切酶分别对融合片段2和载体LoxPneoLoxP2PGK进行双酶切,然后连接得到猪Rosa26基因donor载体。
3.根据权利要求2所述的制备方法,其特征在于,步骤S1所述猪Rosa26基因第1内含子同源左臂核苷酸序列如SEQ ID NO.5所示;步骤S2所述猪Rosa26基因第1内含子同源右臂核苷酸序列如SEQ ID NO.8所示。
4.根据权利要求3所述的制备方法,其特征在于,用于扩增猪Rosa26基因第1内含子同源左臂的引物对的核苷酸序列如SEQ ID NO.6~7所示;用于扩增猪Rosa26基因第1内含子同源右臂的引物对的核苷酸序列如SEQ ID NO.9~10所示。
5.根据权利要求2所述的方法,其特征在于,用于扩增靶向敲除病毒pE248R基因的sgRNA-Cas9基因的引物对的核苷酸序列如SEQ ID NO.3~4所示。
6.一种CRISPR/Cas9打靶载体,其特征在于,其含有特异性靶向猪Rosa26基因第1内含子的sgRNA,所述sgRNA的核苷酸序列如SEQ ID NO.12所示。
7.根据权利要求6所述的CRISPR/Cas9打靶载体,其特征在于,具体制备方法为:先根据sgRNA序列合成互补配对的如SEQ ID NO.13~14所示的寡聚核苷酸px459-F和px459-R,再将寡聚核苷酸在94℃,5min,再35℃,10min后立即放冰上进行退火处理,最后将其与经限制性内切酶BbsI进行酶切过夜并回收的px459骨架载体连接。
8.一种抗非洲猪瘟克隆猪的制备方法,其特征在于,将权利要求6-7任一项所述的CRISPR/Cas9打靶载体与权利1-2任一项所述的猪Rosa26基因donor载体共同转入猪成纤维细胞中,获得阳性细胞克隆;再以阳性细胞克隆为核移植供体细胞,卵母细胞为核移植受体细胞;将克隆胚胎移入猪子宫内妊娠,获得基因敲入后的抗非洲猪瘟克隆猪。
9.根据权利要求8所述的制备方法,其特征在于,所述CRISPR/Cas9打靶载体与猪Rosa26基因donor载体共同转入猪成纤维细胞的具体步骤为:CRISPR/Cas9打靶载体与猪Rosa26基因donor载体按物质的量1:1~4的比例混合,用电穿孔的方法将其转入1x106个猪成纤维细胞。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110370768.8A CN113073114B (zh) | 2021-04-07 | 2021-04-07 | 一种抗非洲猪瘟克隆猪的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110370768.8A CN113073114B (zh) | 2021-04-07 | 2021-04-07 | 一种抗非洲猪瘟克隆猪的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113073114A true CN113073114A (zh) | 2021-07-06 |
CN113073114B CN113073114B (zh) | 2022-11-15 |
Family
ID=76615209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110370768.8A Active CN113073114B (zh) | 2021-04-07 | 2021-04-07 | 一种抗非洲猪瘟克隆猪的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113073114B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114107176A (zh) * | 2021-12-14 | 2022-03-01 | 广东省农业科学院动物卫生研究所 | 一种稳定表达非洲猪瘟CD2v蛋白的CHO细胞系及其构建方法和应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110016546A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Porcine genome editing with zinc finger nucleases |
CN106916820A (zh) * | 2017-05-16 | 2017-07-04 | 吉林大学 | 能有效编辑猪ROSA26基因的sgRNA及其应用 |
CN108285906A (zh) * | 2017-12-29 | 2018-07-17 | 广东温氏食品集团股份有限公司 | 一种定点整合外源dna转基因猪的构建方法 |
CN110484538A (zh) * | 2019-09-11 | 2019-11-22 | 中国农业科学院北京畜牧兽医研究所 | 识别猪ROSA26基因的sgRNA及其编码DNA、基因编辑方法、试剂盒和应用 |
WO2020253537A1 (zh) * | 2019-06-21 | 2020-12-24 | 苏州克睿基因生物科技有限公司 | 一种检测非洲猪瘟病毒的方法和试剂盒 |
US20210017516A1 (en) * | 2019-07-16 | 2021-01-21 | Massachusetts Institute Of Technology | Methods of multiplexing crispr |
CN112522313A (zh) * | 2020-11-25 | 2021-03-19 | 南京启真基因工程有限公司 | 用于构建TPH2基因突变的抑郁症克隆猪核供体细胞的CRISPR/Cas9系统 |
-
2021
- 2021-04-07 CN CN202110370768.8A patent/CN113073114B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110016546A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Porcine genome editing with zinc finger nucleases |
CN106916820A (zh) * | 2017-05-16 | 2017-07-04 | 吉林大学 | 能有效编辑猪ROSA26基因的sgRNA及其应用 |
CN108285906A (zh) * | 2017-12-29 | 2018-07-17 | 广东温氏食品集团股份有限公司 | 一种定点整合外源dna转基因猪的构建方法 |
WO2020253537A1 (zh) * | 2019-06-21 | 2020-12-24 | 苏州克睿基因生物科技有限公司 | 一种检测非洲猪瘟病毒的方法和试剂盒 |
US20210017516A1 (en) * | 2019-07-16 | 2021-01-21 | Massachusetts Institute Of Technology | Methods of multiplexing crispr |
CN110484538A (zh) * | 2019-09-11 | 2019-11-22 | 中国农业科学院北京畜牧兽医研究所 | 识别猪ROSA26基因的sgRNA及其编码DNA、基因编辑方法、试剂盒和应用 |
CN112522313A (zh) * | 2020-11-25 | 2021-03-19 | 南京启真基因工程有限公司 | 用于构建TPH2基因突变的抑郁症克隆猪核供体细胞的CRISPR/Cas9系统 |
Non-Patent Citations (4)
Title |
---|
ALEXANDRA HÜBNER 等: "Efficient inhibition of African swine fever virus replication by CRISPR/Cas9 targeting of the viral p30 gene (CP204L)", 《SCIENTIFIC REPORTS》 * |
IRENE RODRÍGUEZ 等: "The African swine fever virus virion membrane protein pE248R is required for virus infectivity and an early postentry event", 《J VIROL.》 * |
ZICONG XIE 等: "Optimization of a CRISPR/Cas9-mediated Knock-in Strategy at the Porcine Rosa26 Locus in Porcine Foetal Fibroblasts", 《SCI REP.》 * |
无: "世界首例ROSA26基因敲入猪模型诞生", 《中国动物检疫》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114107176A (zh) * | 2021-12-14 | 2022-03-01 | 广东省农业科学院动物卫生研究所 | 一种稳定表达非洲猪瘟CD2v蛋白的CHO细胞系及其构建方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113073114B (zh) | 2022-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190284580A1 (en) | Preparation method for anti-porcine reproductive and respiratory syndrome cloned pig | |
CN108949824A (zh) | 基于HMEJ的方法介导Ipr1定点插入获取转基因牛胎儿成纤维细胞的方法 | |
CN105907758A (zh) | CRISPR-Cas9引导序列及其引物、转基因表达载体及其构建方法 | |
CN110079541B (zh) | 一种构建冠状病毒感染性克隆的方法及其应用 | |
US20230062272A1 (en) | Composition for simultaneously modifying amino acids of site 736 and site 738 of papn gene and application thereof | |
CN107267469B (zh) | 纤毛蛋白嵌合型重组人b型腺病毒及其制备方法 | |
CN117487855B (zh) | 通过对cd163靶向灭活来改善猪类健康的方法 | |
CN110951745A (zh) | Cd163突变基因及其在抑制或阻断猪产生抗体的方法和应用 | |
CN113373119A (zh) | 一种表达非洲猪瘟病毒三基因缺失重组伪狂犬病毒毒株、构建方法及其应用 | |
CN113073114B (zh) | 一种抗非洲猪瘟克隆猪的制备方法 | |
CN104293833A (zh) | 一种基于TALEN 介导的Sp110 巨噬细胞特异打靶载体及重组细胞 | |
CN116445454B (zh) | 一种用于培育抗tgev感染的猪品种的成套系统及其应用 | |
EP1943345B1 (en) | A method for the transfer of episomal vectors into animal cells | |
HU227667B1 (en) | Novel expression vectors and uses thereof | |
WO2021121321A1 (zh) | 一种提高基因编辑效率的融合蛋白及其应用 | |
CN104726495B (zh) | 一种基于talen介导的基因打靶敲除山羊blg的载体及重组细胞 | |
Li et al. | Associated technologies for genome editing | |
CN113444722A (zh) | 单碱基编辑介导的剪接修复在制备治疗脊髓性肌萎缩症中的应用 | |
CN113502299B (zh) | 一种抗金黄色葡萄球菌遗传修饰山羊生产方法 | |
CN116769016B (zh) | pAPN突变体和用于pAPN基因定点修饰的组合物及应用 | |
CN116515775B (zh) | 一种囊膜表达猪圆环病毒2衣壳蛋白的伪狂犬病病毒及其应用 | |
US20220290184A1 (en) | Donor pigs for xenotransplantation | |
CN116855539B (zh) | 一种同时敲除CD163、pAPN、MSTN基因抗病和品质改良猪培育方法 | |
CN111621500B (zh) | 一种基于myl4基因编辑的心房颤动/心房心肌病大鼠模型及其构建方法 | |
WO2012071762A1 (zh) | 制备抗蓝耳病转基因猪的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |